[Pharmacological alteration of the antigenic properties of experimental leukemias detected by lymphocyte transformation].
It has previously been demonstrated that an in vitro antineoplastic treatment may induce new antigenic specificities in murine lymphomas. L1210 leukemia has been altered by DIC (L1210/DIC); drug-treated L1210 subline has been rejected by syngeneic animals. Here spleen cells from mice, normal or immune to L1210/DIC, have been stimulated in vitro by the L1210/DIC cells as measured by 3-h-thymidine uptake. Spleen cell stimulation did not occur with other syngeneic tumor cells and, as expected, spleen cells have been triggered by allogeneic cells. DIC-induced antigens stimulating syngeneic lymphocytes, as allogeneic cells did, have been demonstrated on L1210/DIC cells.
D000818:Animals; D000951:Antigens, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003606:Dacarbazine / Q000494:pharmacology; D007939:Leukemia L1210 / Q000188:drug therapy / Q000276:immunology*; D008213:Lymphocyte Activation; D051379:Mice; D013154:Spleen / Q000276:immunology*
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D003606:Dacarbazine
Alterazione farmacologica delle proprieta antigeniche di leucemie sperimentali evidenziate dalla blastizzazione linfocitaria